← FDA DRUG APPROVALS

FDA ANDA · ANDA090318

ROPIVACAINE HYDROCHLORIDE

Sponsor: RISING

APPLICATION
ANDA090318
TYPE
ANDA
ORIGINAL APPROVAL
2014-09-23
LATEST ACTION
2023-07-23
ROUTE
INJECTION
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued

Products

ROPIVACAINE HYDROCHLORIDEDiscontinued
ROPIVACAINE HYDROCHLORIDE 150MG/30ML (5MG/ML) · SOLUTION · INJECTION
ROPIVACAINE HYDROCHLORIDEDiscontinued
ROPIVACAINE HYDROCHLORIDE 150MG/20ML (7.5MG/ML) · SOLUTION · INJECTION
ROPIVACAINE HYDROCHLORIDEDiscontinued
ROPIVACAINE HYDROCHLORIDE 40MG/20ML (2MG/ML) · SOLUTION · INJECTION
ROPIVACAINE HYDROCHLORIDEDiscontinued
ROPIVACAINE HYDROCHLORIDE 200MG/20ML (10MG/ML) · SOLUTION · INJECTION

Approval history

2023-07-23Labeling · Supplement 7 · standardAP
2023-07-23Labeling · Supplement 5 · standardAP
2014-09-23OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →